ENPICOM, an innovative bioinformatics software company, announced the upcoming expansion of the capabilities of the IGX Platform to unlock seamless analysis of antibody panning data.
This major development will allow researchers to analyze antibody display data in an intuitive and visual way, easily perform multi-dataset comparisons, and identify a diverse set of enriched candidates with the best characteristics.
“Our customer-centric approach to product development gives us a close-up view of the complex analysis workflows required for antibody display screening and how a single, scalable tool can immensely improve speed of analysis and quality of the selected candidates.” said Jos Lunenberg, co-founder and Chief Executive Officer at ENPICOM. “Due to limited, inefficient workflows researchers often have to discard the vast majority of the available NGS data and focus on a small pool of the most frequent clones. We are launching the new IGX-Track App so that our customers can look beyond the tip of the iceberg and make informed decisions with a complete view of their data. Custom analysis workflows and visualizations can be created with a few clicks so scientists can simply select better antibodies faster.”
Enabling streamlined enrichment analysis
Display technologies empower antibody discovery by screening millions of candidates against potential targets. By including different panning round conditions and a variety of antigens, researchers can obtain a robust candidate pool with diverse binding profiles. However, complex analysis workflows – including operations like intersecting, joining, or subtracting datasets – that match the panning campaign design are needed to fully take advantage of the powerful combination of NGS and display screening.
The new IGX-Track App extends the antibody discovery capabilities of the IGX Platform and provides a fast, flexible way to discover a diverse set of enriched candidates with the best characteristics. Scientists can effortlessly compose enrichment analysis workflows that match the design of their panning campaigns and discover candidates that otherwise would have been overlooked.
Scientists using IGX-Track on the IGX Platform will be able to:
- Track clones across panning rounds to identify highly enriched candidates through tabular views and interactive, user-defined visualizations.
- Freely join, intersect, and subtract many datasets to match their panning campaign design.
- Broaden their analysis beyond just the most frequent clones with the platform’s scalable, NGS-ready architecture.
- Easily subtract irrelevant antibodies identified in control panning conditions from the candidates enriched on target.
- Make fully informed choices, while avoiding bias, by overlaying accurate liability predictions, assay data, and more onto enrichment graphs.
The company will launch the new functionality at the Antibody Engineering and Therapeutics conference on June 8 in Amsterdam.
ENPICOM is an innovative bioinformatics software engineering company delivering ground-breaking products and customized solutions to decode the immune system and improve human health. With a diverse team of over 45 experts in various disciplines, ENPICOM serves customers from all over the world, ranging from academic research centers doing basic research related to the immune system, to biotech and global pharmaceutical companies focusing on the discovery and development of novel immunotherapies and vaccines.
Leveraging a unique mix of immunology knowledge, bioinformatics method development, and software engineering skills, ENPICOM offers a world-class repertoire sequencing data analysis solution – the ImmunoGenomiX (IGX) Platform. IGX is an innovative platform to manage, store, analyze, visualize, and interpret immune repertoire sequencing data from T and B cell receptors. Together with its partners, ENPICOM delivers full immune repertoire sequencing and analysis service.
